Envestnet Asset Management
MYGN icon

Envestnet Asset Management’s Myriad Genetics MYGN Stock Holding History

Envestnet Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,363
Closed -$686K – 4517
2025
Q1 		$686K Buy
77,363
+1,336
+2% +$16K ﹤0.01% 3420
2024
Q4 		$1.04M Sell
76,027
-9,351
-11% -$173K ﹤0.01% 3148
2024
Q3 		$2.34M Buy
85,378
+7,604
+10% +$206K ﹤0.01% 2549
2024
Q2 		$1.9M Buy
77,774
+9,838
+14% +$216K ﹤0.01% 2629
2024
Q1 		$1.45M Sell
67,936
-150,819
-69% -$3.24M ﹤0.01% 2782
2023
Q4 		$4.19M Sell
218,755
-2,420
-1% -$41.9K ﹤0.01% 2013
2023
Q3 		$3.55M Buy
221,175
+98,744
+81% +$1.88M ﹤0.01% 2026
2023
Q2 		$2.84M Buy
122,431
+5,330
+5% +$116K ﹤0.01% 2067
2023
Q1 		$2.72M Sell
117,101
-26,721
-19% -$543K ﹤0.01% 2011
2022
Q4 		$2.09M Sell
143,822
-10,507
-7% -$196K ﹤0.01% 2136
2022
Q3 		$2.94M Buy
154,329
+11,228
+8% +$258K ﹤0.01% 1841
2022
Q2 		$2.6M Buy
143,101
+3,561
+3% +$73.9K ﹤0.01% 1932
2022
Q1 		$3.52M Buy
139,540
+8,670
+7% +$222K ﹤0.01% 1828
2021
Q4 		$3.61M Buy
130,870
+7,708
+6% +$223K ﹤0.01% 1783
2021
Q3 		$3.98M Buy
123,162
+11,926
+11% +$396K ﹤0.01% 1669
2021
Q2 		$3.4M Sell
111,236
-3,566
-3% -$103K ﹤0.01% 1741
2021
Q1 		$3.5M Buy
114,802
+21,230
+23% +$603K ﹤0.01% 1616
2020
Q4 		$1.85M Buy
93,572
+12,279
+15% +$198K ﹤0.01% 1799
2020
Q3 		$1.06M Buy
81,293
+2,718
+3% +$34.4K ﹤0.01% 1978
2020
Q2 		$891K Buy
78,575
+21,514
+38% +$306K ﹤0.01% 2037
2020
Q1 		$817K Buy
57,061
+35,724
+167% +$755K ﹤0.01% 1938
2019
Q4 		$581K Buy
21,337
+997
+5% +$27.4K ﹤0.01% 2360
2019
Q3 		$582K Buy
+20,340
New +$593K ﹤0.01% 2275
2017
Q2 		– Sell
-1,516
Closed -$29K – 3095
2017
Q1 		$29K Sell
1,516
-84
-5% -$1.49K ﹤0.01% 2591
2016
Q4 		$28K Buy
1,600
+469
+41% +$8.48K ﹤0.01% 2593
2016
Q3 		$23K Buy
+1,131
New +$28.7K ﹤0.01% 2792
2016
Q2 		– Sell
-1,069
Closed -$40K – 3121
2016
Q1 		$40K Sell
1,069
-551
-34% -$20.8K ﹤0.01% 2798
2015
Q4 		$70K Sell
1,620
-1,151
-42% -$48.6K ﹤0.01% 2529
2015
Q3 		$104K Buy
+2,771
New +$98.3K ﹤0.01% 2334
2015
Q1 		– Sell
-2,000
Closed -$68K – 2272
2014
Q4 		$68K Sell
2,000
-472
-19% -$16.7K ﹤0.01% 1294
2014
Q3 		$95K Sell
2,472
-17,077
-87% -$637K ﹤0.01% 1308
2014
Q2 		$761K Sell
19,549
-618
-3% -$23K 0.01% 643
2014
Q1 		$690K Sell
20,167
-23,311
-54% -$722K 0.01% 571
2013
Q4 		$912K Buy
43,478
+14,282
+49% +$361K 0.01% 472
2013
Q3 		$686K Buy
29,196
+689
+2% +$19.6K 0.01% 532
2013
Q2 		$766K Buy
+28,507
New +$826K 0.01% 465

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Envestnet Asset Management's MYGN Position: Q2 2025 in Review

Envestnet Asset Management sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 77,363 shares — an estimated $686K sold.

Envestnet Asset Management first reported a position in MYGN in Q2 2013 and held it in 36 quarters. The position peaked at $4.19M in Q4 2023. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Envestnet Asset Management reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 77,363 Myriad Genetics shares in Q2 2025, an estimated $686K.
  • Envestnet Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 36 quarters.
  • Envestnet Asset Management's Myriad Genetics position peaked at $4.19M in Q4 2023.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.